Wednesday - July 9, 2025

LOGIN  |  REGISTER
Recursion

Collegium Pharmaceutical to Participate in H.C. Wainwright 26th Annual Global Investment Conference

August 30, 2024 | Last Trade: US$31.96 0.37 1.17

STOUGHTON, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference being held in New York, NY from September 9-11, 2024.

Details of the event are as follows:
Fireside Chat Date and Time: Monday, September 9, 2024, at 12:30 p.m. ET

The fireside chat will be webcast live and can be accessed from the Investors section of the Company's website: https://ir.collegiumpharma.com A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Collegium Pharmaceutical, Inc.

Collegium is a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.

Investor Contact:
Christopher James, M.D.                                                                                       
Vice President, Investor Relations
ir@collegiumpharma.com 

Media Contact:
Marissa Samuels
Vice President, Corporate Communications
communications@collegiumpharma.com 

C4 Therapeutics

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page